ImmunoACT

Join our latest webinar with Dr Kunal Goyal! Explore how anti-CD19 CAR-T therapy is used in real-world with NexCAR19 for relapsed/refractory B-cell lymphomas, overcoming trial limitations, managing toxicity, and achieving MRD-negative outcomes with CNS involvement. Register for free via the link below!

𝐋𝐢𝐧𝐝𝐚'𝐬 𝐣𝐨𝐮𝐫𝐧𝐞𝐲 𝐰𝐢𝐭𝐡 𝐍𝐞𝐱𝐂𝐀𝐑𝟏𝟗 Linda Becht, a Dutch national, received NexCAR19 at Artemis Hospitals, Gurugram, under the care of the cell therapy team led by Dr. Gaurav Dixit. Her journey is an example of how patients who would have been ineligible to receive Anti-CD19 CAR-T cell therapy due to high risk factors and pre-existing conditions, can still have a fighting chance at remission with NexCAR19, owing to humanized design of the drug, combined with its timely clinical management that results in a superior safety profile marked by fewer and less severe toxicities. Consult your hematologist or medical oncologist on whether NexCAR19 is suitable for you!! Rahul Purwar Shirish Arya Atharva Karulkar Shreshtha Shah Afrin Rafiq Juber Pendhari Manivasagam S Anand Vaibhaw Karan Gera Akhilesh Kumar Pandey U HARI KRISHNAN Advanced Centre for Treatment, Research and Education in Cancer(ACTREC) TATA MEMORIAL HOSPITAL Alliance for Regenerative Medicine Society for Innovation & Entrepreneurship -SINE IIT Bombay Indian Council of Medical Research (ICMR) ImmunoACT Biotechnology Industry Research Assistance Council (BIRAC) #CARTCellTherapy #Immunotherapy #CancerTreatment #LymphomaRecovery #InnovationInHealthcare

Happy Makar Sankranti and Pongal, may the harvest of happiness, success, and prosperity fill your life with endless joy and blessings!🎉

𝐍𝐞𝐱𝐂𝐀𝐑𝟏𝟗 in the real-world (r/r B-NHLs & B-ALL): A snapshot of 100+ commercially treated patients [ASH 2024]: ✅ Efficacy: B-NHLs: 73% CR, B-ALL: 92% CR (1 month) ✅ Safety: <20% incidence of Grade III/IV toxicities, <10% incidence of Grade III/IV CRS or ICANS ✅ Access: ~15 days for a slot, ~16 days for manufacturing turnaround, Median 26 days from vein-to-vein, >99% manufacturing success rate. A snapshot and forerunner of the scalability, reproducibility & accessibility of autologous CAR-T cell therapies highlighted by distinguished efficacy and low supplementary healthcare resource utilization. Rahul Purwar Shirish Arya Atharva Karulkar Shreshtha Shah Afrin Rafiq Juber Pendhari Manivasagam S Anand Vaibhaw Hasmukh Jain Dr. Ashutosh Tripathi Karan Gera Advanced Centre for Treatment, Research and Education in Cancer(ACTREC) Tata Memorial Centre Alliance for Regenerative Medicine Society for Innovation & Entrepreneurship -SINE IIT Bombay Indian Council of Medical Research (ICMR) ImmunoACT Biotechnology Industry Research Assistance Council (BIRAC) #ASH2024 #CAR_TCellTherapy #OncologyInnovation #HealthcareTransformation

We're pleased to announce that we have taken the first steps towards broadening access to 𝐍𝐞𝐱𝐂𝐀𝐑𝟏𝟗 beyond India, through a clinical collaboration with IPN & INCMNSZ in Mexico. Our mission to provide innovative, accessible and affordable CAR-T cell therapies remains strong as ever. #GlobalHealthInnovation #CAR_TCellTherapy #NexCAR19 #MedicalAdvancements #HealthcareCollaboration #AffordableHealthcare

As we continue our mission to make CAR-T therapy accessible to all, we are excited to share key milestones from 2024 and a sneak peek at 2025: 1. Over 𝟐𝟓𝟎+ 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐭𝐫𝐞𝐚𝐭𝐞𝐝 with NexCAR19 (Talicabtagene autoleucel), demonstrating world-class efficacy and unmatched safety. 2. 𝟒𝟓+ 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐡𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐬 across India have adopted NexCAR19 in the last year, revolutionizing treatment for B-ALL and B-NHL in refractory/relapsed settings. (Real-world data in the first 100 infused patients presented at ASH 2024). 3. Our pipeline continues to advance with our 𝐀𝐧𝐭𝐢-𝐁𝐂𝐌𝐀 𝐂𝐀𝐑-𝐓 𝐟𝐨𝐫 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐌𝐲𝐞𝐥𝐨𝐦𝐚 expected to enter clinical trials this year (pre-clinical data presented at ASH 2024). 4. Our upcoming 𝐬𝐭𝐚𝐭𝐞-𝐨𝐟-𝐭𝐡𝐞-𝐚𝐫𝐭 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐲 𝐢𝐧 𝐍𝐚𝐯𝐢 𝐌𝐮𝐦𝐛𝐚𝐢 is aimed to be operational by the end of 2025 to scale operations, expand access, and improve affordability & accessibility of our CAR-T cell therapies 5. Publication alert: NexCAR19 Phase I & II data will soon feature in 𝐋𝐚𝐧𝐜𝐞𝐭 𝐇𝐞𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲. We are deeply grateful to our partners for their unwavering support and look forward to a brighter 2025 for patients in need. Shirish Arya Rahul Purwar Karan Gera Atharva Karulkar ImmunoACT Indian Institute of Technology, Bombay Advanced Centre for Treatment, Research and Education in Cancer(ACTREC) Tata Memorial Centre Society for Innovation & Entrepreneurship -SINE IIT Bombay Biotechnology Industry Research Assistance Council (BIRAC) Government of India Official ISCT, International Society for Cell & Gene Therapy #CellandGeneTherapy #CAR_TCellTherapy #NexCAR19

The latest in our interactive webinar series is by Dr Kunal Goyal, on the use of anti-CD19 CAR-T cell therapy, particularly in the real-world with NexCAR19, in the context of relapsed/refractory B-cell Non-Hodgkin's Lymphoma with CNS involvement. Register here!

🎥 Kuldeep Dubey's Inspiring Journey with NexCAR19™ #ImmunoACT #CAR_TCellTherapy #PatientJourneyTestimonial #HealthcareInnovation #CancerRemission Rahul Purwar Shirish Arya Atharva Karulkar Advanced Centre for Treatment, Research and Education in Cancer(ACTREC) ImmunoACT Carl June National Cancer Institute (NCI) Indian Institute of Technology, Bombay Government of India (GoI) ISCT, International Society for Cell & Gene Therapy Biotechnology Industry Research Assistance Council (BIRAC) Cell & Gene Therapy Insights Indian Council of Medical Research (ICMR) Tata Memorial Centre Department of Biotechnology Department of Science and Technology

ImmunoACT Featured in the Times of India! 🎉 We’ve received a special feature mention in the Medical Breakthroughs of 2024 by the Times of India [January 1, 2025]! ImmunoACT continues to strive to broaden, expand, and improve access to NexCAR19 (Talicabtagene autoleucel), a potentially life-saving CAR T-cell therapy for the treatment of B-cell lymphomas & B-cell acute lymphoblastic leukaemia in settings where frontline or subsequent therapies have been inadequate to achieve a response. #MedicalBreakthroughs #TimesOfIndia #ImmunoACT #CAR_TCellTherapy #InnovationInHealthcare

Cheers to a New Year filled with growth, innovation, and endless possibilities! Let's continue transforming lives with passion and purpose in 2025.🎉